Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: BioChaperone® Combo;   Drug: Humalog® Mix25;   Drug: Humalog®;   Drug: Lantus®;   Drug: Placebo
Sponsor:   Adocia
Not yet recruiting - verified September 2016

Preprandial Ghrelin Effect

Condition:   Type 2 Diabetes
Interventions:   Drug: ghrelin;   Other: Saline
Sponsors:   Jenny Tong, MD, MPH;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified September 2016

A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin degludec/insulin aspart;   Drug: Insulin glargine;   Drug: Insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016

Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Not yet recruiting - verified September 2016

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016

Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: Continuous subcutaneous insulin infusion
Sponsors:   King's College London;   University of Leicester;   University Hospital, Caen
Active, not recruiting - verified September 2016

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Intervention:   Drug: IW-1973 Tablet & Placebo to match
Sponsor:   Ironwood Pharmaceuticals, Inc.
Not yet recruiting - verified September 2016

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Diabetic Nephropathy
Interventions:   Drug: Dapagliflozine 10 mg once daily tablet treatment;   Drug: Placebo identical once daily tablet treatment
Sponsor:   Peter Rossing
Recruiting - verified September 2016

Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Lawson Health Research Institute;   AstraZeneca
Not yet recruiting - verified September 2016

Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes

Conditions:   Type II Diabetes;   Periodontal Disease
Interventions:   Behavioral: Motivational Interviewing;   Procedure: Dental cleaning
Sponsors:   Massachusetts General Hospital;   Harvard School of Dental Medicine
Not yet recruiting - verified September 2016

Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway

Condition:   Healthy Volunteers
Interventions:   Device: Vagus Nerve Stimulation;   Device: Sham Vagus Nerve Stimulation
Sponsor:   Northwell Health
Recruiting - verified September 2016

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Dapagliflozin;   Drug: Metformin
Sponsors:   The University of Texas Health Science Center at San Antonio;   AstraZeneca
Not yet recruiting - verified September 2016

Impact of a Sexology Consultation on Disease Control of Type 2 Male Diabetics With Erectile Dysfunction

Conditions:   Erectile Dysfunction;   Type 2 Diabetes
Intervention:   Procedure: Sexology consultation
Sponsor:   Centre Hospitalier Universitaire de la Réunion
Recruiting - verified September 2016

Curcumin Supplement in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Nonalcoholic Fatty Liver
Interventions:   Dietary Supplement: curcumin;   Dietary Supplement: placebo
Sponsor:   National Nutrition and Food Technology Institute
Not yet recruiting - verified September 2016

Translation, Cultural Adaptation and Validation of the Creole Versions of the EQ-5D and the SF-36 Questionnaires in Patients With Type II Diabetes in Reunion Island, Martinique and Guadeloupe

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   Centre Hospitalier Universitaire de la Réunion;   Centre d'investigation Clinique 1410
Recruiting - verified September 2016

Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes

Conditions:   Prediabetes;   Obesity;   Overweight
Intervention:   Behavioral: Lifestyle Intervention
Sponsors:   Centro de Investigación en Alimentación y Desarrollo A.C.;   Universidad de Sonora
Recruiting - verified September 2016

Feasibility Study of Metformin Therapy in ADPKD

Condition:   Polycystic Kidney, Autosomal Dominant
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not yet recruiting - verified September 2016

Linagliptin Add-on to Insulin Background Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin;   Drug: background therapy
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified September 2016

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Obesity
Interventions:   Drug: canagliflozin;   Drug: Placebo (for canagliflozin)
Sponsors:   The Cleveland Clinic;   Janssen Scientific Affairs, LLC
Not yet recruiting - verified September 2016

Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices

Condition:   Diabetes Mellitus
Interventions:   Device: Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose;   Other: Point of Care (POC) blood glucose
Sponsor:   University of Maryland
Not yet recruiting - verified September 2016

Arming Health: Can Breaking up Restful Sitting Time With Upper Body Contractile Activity Regulate Metabolic Health.

Condition:   Diabetes
Interventions:   Other: Prolonged Sitting;   Other: Light arm ergometry breaks
Sponsors:   University of Leicester;   National Institute for Health Research, United Kingdom;   National Health Service, United Kingdom
Recruiting - verified August 2016

The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion

Condition:   Diabetes Type Two
Intervention:   Drug: Hydroxychloroquine
Sponsor:   Hadassah Medical Organization
Not yet recruiting - verified August 2016

Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Drug: Insulin glargine;   Drug: Non-insulin antihyperglycemic drugs
Sponsor:   Sanofi
Recruiting - verified September 2016

Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus

Condition:   Diabetes
Interventions:   Other: Boost Glucose Control (A);   Other: Boost Glucose Control (B);   Other: Boost Original
Sponsor:   Nestlé
Completed - verified July 2016

ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus

Condition:   Diabetes Mellitus Type 2
Intervention:   Behavioral: Shared Decision Making
Sponsors:   AstraZeneca;   Brigham Women's Health
Not yet recruiting - verified September 2016

Whey Protein Effect on Glycaemic and Appetite Responses in T2D

Conditions:   Type II Diabetes Mellitus;   Glucose Metabolism Disorders;   Metabolic Diseases
Interventions:   Dietary Supplement: Whey Protein;   Dietary Supplement: Hydrolysed Protein;   Dietary Supplement: Placebo
Sponsor:   Northumbria University
Active, not recruiting - verified August 2016

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

Condition:   Diabetes Mellitus Type 2
Intervention:  
Sponsors:   AstraZeneca;   Truven health
Recruiting - verified September 2016

Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016

Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE;   Drug: metformin;   Drug: repaglinide;   Drug: acarbose;   Drug: sitagliptin
Sponsor:   Sanofi
Recruiting - verified September 2016

Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: Bexagliflozin
Sponsor:   Theracos
Recruiting - verified September 2016

A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Lixisenatide (AVE0010);   Drug: Placebo;   Drug: Basal Insulin;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified September 2016

A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Metformin IR
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Dapagliflozin Patient Satisfaction Survey

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Optum
Recruiting - verified September 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: insulin glargine/lixisenatide fixed ratio combination;   Drug: liraglutide;   Drug: exenatide;   Drug: exenatide extended-release;   Drug: albiglutide;   Drug: dulaglutide;   Drug: metformin;   Drug: pioglitazone
Sponsor:   Sanofi
Recruiting - verified September 2016

A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

Conditions:   Healthy;   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LY3298176;   Drug: Placebo;   Drug: Dulaglutide
Sponsor:   Eli Lilly and Company
Recruiting - verified September 2016

Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Hypertension
Interventions:   Drug: Dapagliflozin;   Drug: Sulfonylurea;   Drug: Placebo
Sponsors:   Tulane University;   AstraZeneca
Recruiting - verified September 2016

A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: insulin degludec/liraglutide
Sponsor:   Novo Nordisk A/S
Enrolling by invitation - verified September 2016

A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified September 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine (HOE901);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified September 2016

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Insulin glargine U100 (HOE901);   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified September 2016

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010);   Drug: Lixisenatide (AVE0010);   Drug: Oral anti-diabetic drugs
Sponsor:   Sanofi
Recruiting - verified September 2016

A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia

Conditions:   Hypercholesterolemia;   Mixed Dyslipidemia;   Type 2 Diabetes
Interventions:   Biological: Evolocumab;   Other: Placebo to Evolocumab
Sponsor:   Amgen
Recruiting - verified September 2016

Randomized Sitagliptin Withdrawal Study (MK-0431-845)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo to stiagliptin;   Drug: Metformin;   Drug: Metformin XR;   Drug: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin placebo
Sponsors:   AstraZeneca;   Parexel;   Q2 solutions;   PRA Health Sciences;   Covance Laboratories, Inc
Recruiting - verified September 2016

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: Insulin degludec;   Drug: GLP-1 receptor agonist;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Sanofi
Recruiting - verified September 2016

A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin L-proline;   Drug: Metformin;   Drug: Placebo
Sponsor:   Astellas Pharma Europe B.V.
Recruiting - verified September 2016

Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Procedure: EUS and OCT imaging
Sponsor:   Victoria Gomez
Enrolling by invitation - verified September 2016

An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: No Intervention
Sponsor:   Janssen Inc.
Recruiting - verified September 2016

Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications

Condition:   Acute Kidney Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Acute Liver Injury in Patients on Dapagliflozin

Condition:   Acute Liver Injury
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Complications of UTI in Patients on Dapagliflozin

Condition:   Severe Complications of Urinary Tract Infections
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

Conditions:   Breast Cancer;   Bladder Cancer
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified September 2016

A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Placebo for Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes

Condition:   Non Alcoholic Fatty Liver Disease
Intervention:   Drug: Empagliflozin
Sponsor:   Medanta, The Medicity, India
Recruiting - verified September 2016

Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Lyophilized albiglutide DCC pen injector;   Drug: Lyophilized albiglutide DCC pen injector matching placebo;   Drug: Albiglutide liquid auto-injector;   Drug: Albiglutide liquid auto-injector matching placebo
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified September 2016

Metformin Immunotherapy in HIV Infection

Condition:   HIV Infection
Intervention:   Drug: Metformin
Sponsor:   McGill University Health Center
Recruiting - verified September 2016

Effect of Sitagliptin on Progression of Coronary Intermediate Lesion

Conditions:   Atherosclerosis;   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo
Sponsor:   Li Bo
Recruiting - verified September 2016

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

Condition:   Dyslipidemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: statins;   Drug: ezetimibe;   Drug: fenofibrate;   Drug: nicotinic acid;   Drug: omega-3 fatty acids
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Recruiting - verified September 2016

A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics

Condition:   Type 1 Diabetes
Intervention:   Device: Harmony 1 Sensors
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified September 2016

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Recruiting - verified September 2016

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo matching ertugliflozin;   Drug: Metformin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified September 2016

Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified September 2016

Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: sitagliptin;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified September 2016

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified September 2016

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Active, not recruiting - verified September 2016

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Condition:   Hypercholesterolaemia
Interventions:   Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo;   Drug: insulin;   Drug: insulin;   Drug: statin;   Drug: lipid modifying therapy
Sponsors:   Sanofi;   Regeneron Pharmaceuticals
Active, not recruiting - verified September 2016

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Recruiting - verified September 2016

Toronto Gestational Glucose Tolerance Cohort

Condition:   Type 2 Diabetes, Gestational Diabetes, Pre-diabetes
Intervention:   Other: There is no intervention. An exposure of interest is glucose tolerance status in pregnancy
Sponsors:   Mount Sinai Hospital, Canada;   Canadian Institutes of Health Research (CIHR)
Recruiting - verified September 2016

Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes

Conditions:   Diabetes;   Periodontitis
Interventions:   Device: Hyperbaric Oxygen therapy;   Other: Conventional Wound Therapies
Sponsor:   Loma Linda University
Recruiting - verified September 2016

Continuation of Metformin to Improve And Keep Peri-operative Glycemic Control

Condition:   Diabetes Mellitus Type 2
Interventions:   Drug: Metformin;   Drug: Placebo
Sponsor:   McMaster University
Not yet recruiting - verified September 2016

Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified September 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Completed - verified September 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified September 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified September 2016

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents

Condition:   Diabetes Mellitus, Type 2 (T2DM)
Interventions:   Device: Bolus Insulin Patch (Calibra Finesse);   Device: Insulin Pen (Novo-Nordisk FlexPen®)
Sponsors:   Calibra Medical, Inc.;   Medpace, Inc.
Active, not recruiting - verified September 2016

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

Conditions:   Type 2 Diabetes;   Metabolic Syndrome
Intervention:   Drug: PBI4050
Sponsor:   ProMetic BioSciences Inc.
Active, not recruiting - verified September 2016

A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin;   Drug: Sulfonylurea
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Short Term Dietary Serine Supplementation and Circulating Serine Levels

Condition:   Serine
Intervention:   Dietary Supplement: L-serine
Sponsor:   Massachusetts General Hospital
Withdrawn - verified September 2016

Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes
Intervention:   Procedure: Doubly labelled water method
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Recruiting - verified September 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Recruiting - verified September 2016

A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified September 2016

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Active, not recruiting - verified September 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Conditions:   Type 2 Diabetes Mellitus,;   Inadequate Glycaemic Control
Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Glimepiride;   Drug: Placebo for dapagliflozin;   Drug: Placebo for saxagliptin;   Drug: Placebo for glimepiride
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2016

Linagliptin Effect on CD34+ Stem Cells

Conditions:   Type 2 Diabetes;   Impaired Renal Function
Interventions:   Drug: Linagliptin;   Drug: Placebo
Sponsors:   George Washington University;   Boehringer Ingelheim
Recruiting - verified September 2016

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified September 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified September 2016

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Harmony 1 Sensor
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified September 2016

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: KQ-791;   Drug: Placebo
Sponsor:   Kaneq Bioscience Limited
Completed - verified September 2016

Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death

Conditions:   Tissue and Organ Harvesting;   Liver Transplantation;   Brain Death
Intervention:   Procedure: Fibroscan
Sponsor:   University Hospital, Limoges
Recruiting - verified September 2016

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Completed - verified September 2016

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2016

Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences

Condition:   Diabetes Mellitus
Interventions:   Device: OneTouch Reveal® Mobile APP;   Device: OneTouch Verio® Flex BGMS
Sponsors:   LifeScan;   Bio-Kinetic Europe, Ltd.
Completed - verified September 2016

Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Diabetes Mellitus
Intervention:   Device: DMR Procedure (Fractyl)
Sponsor:   Fractyl Laboratories, Inc.
Recruiting - verified September 2016

Add Glucokinase Activator to Target A1c

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: TTP399 400 mg;   Drug: TTP399 800 mg;   Drug: Sitagliptin 100 mg;   Drug: Placebo
Sponsor:   vTv Therapeutics
Completed - verified September 2016

Alveolar Bone Changes in Diabetes (ABCD) Study

Condition:   Diabetes Mellitus
Interventions:   Device: Well-controlled diabetic (WC);   Device: Poorly controlled diabetics (PC)
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   University of Washington;   The University of Texas Health Science Center, Houston
Recruiting - verified September 2016

Strength Training Regimen for Normal Weight Diabetics

Condition:   Diabetes Mellitus
Intervention:   Behavioral: Exercise Intervention
Sponsors:   Stanford University;   Pennington Biomedical Research Center
Recruiting - verified September 2016

Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Jardiance
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified September 2016

Effects of Physical Exercise on Blood Glucose and Pain From the Muskuloskeletal System in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Exercise training
Sponsor:   Nordsjaellands Hospital
Recruiting - verified September 2016

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Condition:   Healthy Volunteers
Interventions:   Drug: Placebo;   Drug: Roflumilast/Sitagliptin;   Drug: Sitagliptin;   Drug: Roflumilast
Sponsor:   National Institute on Aging (NIA)
Completed - verified September 2016

A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Motus Therapeutics, Inc.
Completed - verified September 2016

A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria

Condition:   Diabetic Nephropathy
Interventions:   Drug: CS-3150;   Drug: placebo
Sponsor:   Daiichi Sankyo Inc.
Completed - verified September 2016

Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes

Conditions:   Peripheral Artery Disease;   Type 2 Diabetes
Interventions:   Drug: Aspirin;   Drug: Ticagrelor;   Drug: Aspirin Placebo;   Drug: Ticagrelor Placebo
Sponsor:   Icahn School of Medicine at Mount Sinai
Recruiting - verified September 2016

Adult Subjects With Uncontrolled Type 2 Diabetes

Condition:   Type 2 Diabetes
Intervention:   Drug: MLR-1023
Sponsors:   Melior Pharmaceuticals;   Bukwang Pharmaceutical, Co., Ltd.
Completed - verified September 2016

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: placebo
Sponsor:   Novo Nordisk A/S
Completed - verified September 2016

An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System

Condition:   Type 2 Diabetes
Intervention:   Device: EndoBarrier
Sponsor:   GI Dynamics
Withdrawn - verified November 2014

Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Procedure: Roux-en-Y gastric bypass surgery;   Behavioral: Low-calorie diet;   Procedure: BPD;   Procedure: SG;   Procedure: LAGB
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified September 2016

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

Condition:   Polycystic Ovarian Syndrome
Interventions:   Other: Paleolithic diet;   Other: American Diabetes Association diet
Sponsor:   University of California, San Francisco
Recruiting - verified September 2016

The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy

Conditions:   Diabetes Mellitus;   Type I Diabetes;   Type II Diabetes;   Diabetic Peripheral Neuropathy;   Chronic Pain
Intervention:   Behavioral: Mindfulness Based Stress Reduction
Sponsors:   Ottawa Hospital Research Institute;   Canadian Diabetes Association
Completed - verified May 2016

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes

Condition:   Diabetes
Intervention:   Drug: second- or third-line glucose-lowering diabetes treatment
Sponsors:   NIHR Exeter Clinical Research Facility;   University of Exeter;   Royal Devon and Exeter NHS Foundation Trust;   King's College London;   King's College Hospital NHS Trust;   University of Glasgow;   NHS Greater Glasgow and Clyde;   Newcastle University;   Newcastle-upon-Tyne Hospitals NHS Trust;   Oxford University Hospitals NHS Trust
Completed - verified September 2016

Phase III Insulin Add-On Asia Regional Program - ST

Condition:   Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Dapagliflozin Placebo
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified September 2016

Aldosterone, Microvascular Function and Salt-sensitivity

Conditions:   Abdominal Obesity;   Metabolic Syndrome;   Sodium-sensitivity;   Insulin Resistance;   Hypertension
Interventions:   Dietary Supplement: Low-sodium diet;   Dietary Supplement: High-sodium diet
Sponsor:   Maastricht University Medical Center
Recruiting - verified September 2016

Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study

Condition:   Diabetes Mellitus
Intervention:   Behavioral: Structured Group Exercise
Sponsor:   Stanford University
Recruiting - verified September 2016

Risk Identification of the GlucoTab System in Routine Use

Condition:   Diabetes Mellitus
Intervention:  
Sponsor:   Medical University of Graz
Recruiting - verified September 2016

Effect of Saxagliptin EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: placebo
Sponsors:   George Washington University;   AstraZeneca
Active, not recruiting - verified March 2016

Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease

Conditions:   Renal Insufficiency, Chronic;   Kidney Failure, Chronic
Intervention:   Other: eHealth Intervention
Sponsors:   University of California, San Francisco;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Active, not recruiting - verified September 2016

Mechanisms and Reversibility of Heart Failure Associated With Diabetes

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   Dr. Peter Swoboda
Completed - verified September 2016

Metabolomics During Testosterone Therapy

Condition:   Testosterone Deficiency
Intervention:   Drug: Testosterone Therapy
Sponsor:   Men's Health Boston
Active, not recruiting - verified September 2016

forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Condition:   Type 2 Diabetes
Intervention:   Drug: Forxiga
Sponsors:   AstraZeneca;   Monash University
Terminated - verified September 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2016

Effects of Caloric Restriction in Obesity and Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Behavioral: Calorie restriction (25%);   Behavioral: Ad libitum health diet
Sponsors:   Mario Negri Institute for Pharmacological Research;   Istituto Superiore di Sanità
Recruiting - verified September 2016

A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta duo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified September 2016

Explorative Assessment of Biomarkers in Overweight and Obese Subjects

Condition:   Prediabetes
Intervention:  
Sponsor:   Profil Institut für Stoffwechselforschung GmbH
Recruiting - verified September 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified September 2016

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified September 2016

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: semaglutide;   Drug: exenatide
Sponsor:   Novo Nordisk A/S
Completed - verified September 2016

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Metformin XR;   Drug: Metformin IR;   Drug: Placebo matching with Metformin XR;   Drug: Placebo matching with Metformin IR
Sponsor:   Bristol-Myers Squibb
Completed - verified January 2016

Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: Faster-acting insulin aspart;   Drug: insulin aspart;   Drug: insulin glargine
Sponsor:   Novo Nordisk A/S
Completed - verified September 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2016

The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes

Condition:   Gestational Diabetes Mellitus in Pregnancy
Interventions:   Other: Subjects with Gestational Diabetes;   Other: Controls without Gestational Diabetes
Sponsor:   University of Florida
Recruiting - verified September 2016

Korean Post-marketing Surveillance for Kombiglyze XR®

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsor:   AstraZeneca
Completed - verified September 2016

Better Diabetes Control, Quality - Educate to Achieve Compliance.

Condition:   Diabetes Type 2
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified September 2016

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events

Conditions:   Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   The TIMI Study Group;   Hadassah Medical Organization
Active, not recruiting - verified September 2016

A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trajenta tablet
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified September 2016

A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use

Conditions:   Diabetes Mellitus Type I;   Diabetes Mellitus Type II
Intervention:   Other: EHR Based Strategy to promote Safe and Appropriate Drug Use
Sponsors:   Northwestern University;   University of Illinois at Chicago
Completed - verified September 2016

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified September 2016

The VALIDATE-D Study

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: Calcitriol and Lisinopril;   Drug: Placebo
Sponsor:   Brigham and Women's Hospital
Completed - verified September 2016

Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Placebo and Castration;   Drug: Metformin and Castration
Sponsor:   Devalingam Mahalingam
Completed - verified September 2016

Korean Post-marketing Surveillance for Onglyza®

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: No Intervention (subjects were previously treated with Onglyza®)
Sponsor:   AstraZeneca
Completed - verified September 2016

Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis

Conditions:   Diabetes Mellitus;   Diabetes Mellitus Complications;   Gastroparesis
Interventions:   Drug: RM-131;   Drug: Placebo
Sponsor:   Motus Therapeutics, Inc.
Completed - verified September 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified September 2016

Effects of Acute Exercise on Acetylcarnitine Concentration in Endurance Trained and Untrained Subjects

Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Cycling
Sponsor:   Maastricht University Medical Center
Completed - verified July 2012

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Step Monitoring to Improve ARTERial Health

Conditions:   Type 2 Diabetes;   Hypertension
Interventions:   Behavioral: Step count prescription;   Behavioral: Usual care
Sponsors:   McGill University Health Center;   Canadian Institutes of Health Research (CIHR)
Active, not recruiting - verified September 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified September 2016

Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Type II Diabetes

Condition:   Diabetes Mellitus Type II
Intervention:   Procedure: Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)
Sponsor:   Ageless Regenerative Institute
Recruiting - verified September 2016

Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Intervention:   Drug: liraglutide
Sponsor:   Novo Nordisk A/S
Completed - verified September 2016

Risk of Acute Kidney Injury Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   University of Pennsylvania
Completed - verified September 2016

The TANTALUS® II for the Treatment of Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Device: Tantalus System;   Device: TANTALUS system
Sponsor:   MetaCure (USA), Inc.
Completed - verified September 2016

TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Device: TANTALUS System
Sponsor:   MetaCure (USA), Inc.
Terminated - verified June 2011

Grain Exercise Trial - Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss

Conditions:   Abdominal Obesity;   Cardiovascular Diseases;   Diabetes Type 2;   Hypertension;   Overweight
Interventions:   Behavioral: Diet A;   Behavioral: Diet B;   Behavioral: Physiotherapy
Sponsors:   Lund University;   Region Skane
Completed - verified September 2016

Collection of Blood for Gene Expression/Genomic Studies in Individuals With Diabetes (Qatar)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   Weill Medical College of Cornell University;   Weill Cornell Medical College in Qatar;   Hamad Medical Corporation
Suspended - verified September 2016

Risk of Hospitalized Infections Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatment

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   University of Pennsylvania
Completed - verified September 2016

Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   University of Pennsylvania
Completed - verified September 2016

Risk of Cardiovascular Events in Patients With Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   University of Pennsylvania
Completed - verified September 2016

Risk of Hospitalization for Severe Hypersensitivity (Including Severe Skin Reactions) in Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments

Condition:   Diabetes Mellitus, Type 2
Intervention:  
Sponsors:   AstraZeneca;   Bristol-Myers Squibb;   University of Pennsylvania
Completed - verified September 2016

Low Glycemic Index Diet for Type 2 Diabetics

Condition:   Type 2 Diabetes
Interventions:   Dietary Supplement: low glycemic diet instruction;   Dietary Supplement: high cereal fibre diet instruction
Sponsors:   University of Toronto;   Canadian Institutes of Health Research (CIHR)
Completed - verified September 2016

The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects

Conditions:   Weight Loss;   Obesity
Interventions:   Drug: Byetta (exenatide);   Behavioral: Weight loss;   Other: Metabolic Chamber;   Drug: Placebo
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified November 2015

Genetics of Type 2 Diabetes Among Han Chinese

Conditions:   Diabetes;   Obesity;   Hypertension;   Retinopathy;   Nephropathy
Intervention:  
Sponsor:   National Human Genome Research Institute (NHGRI)
Completed - verified September 2016

A Prospective, Clinical Trial of the TANTALUS® System in Treatment of Obese to Morbidly Obese Patients

Conditions:   Type 2 Diabetes;   Obesity
Intervention:   Device: rechargeable TANTALUS II
Sponsor:   MetaCure (USA), Inc.
Completed - verified April 2013

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified September 2016

Preventing Microalbuminuria in Type 2 Diabetes

Condition:   Diabetes
Interventions:   Drug: Benazepril;   Drug: Valsartan;   Drug: Benazepril/Valsartan
Sponsors:   Mario Negri Institute for Pharmacological Research;   Agenzia Italiana del Farmaco
Completed - verified September 2016

Rosiglitazone on Microalbuminuria in Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Comparison of the Efficacy and Tolerability of the Addition of AVANDIA to Submaximal Doses of Metformin

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Time Course of the Antiproteinuric and Blood Pressure Lowering Effects After Initiation of Renin Inhibition With Aliskiren in Type 2 Diabetes

Condition:   Diabetes Type 2
Intervention:   Drug: Aliskiren
Sponsor:   Novartis
Completed - verified September 2016

Fluid Retention in Rosiglitazone Treated Subjects With Autonomic Neuropathy.

Condition:   Neuropathy, Diabetic
Intervention:   Drug: rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Paleolithic Diet in the Treatment of Glucose Intolerance

Conditions:   Hyperglycemia;   Coronary Heart Disease
Intervention:   Behavioral: Paleolithic diet vs Mediterranean diet
Sponsor:   Lund University Hospital
Completed - verified September 2016

AVANDIA With Glyburide In African American And Hispanic Patients With Type 2 Diabetes Not Controlled by Glyburide Alone

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: rosiglitazone
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Examining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.

Condition:   Diabetes Mellitus
Interventions:   Drug: Rosiglitazone;   Drug: spironolactone;   Drug: hydrochlorothiazide;   Drug: frusemide
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Rosiglitazone;   Drug: glyburide;   Drug: metformin
Sponsor:   GlaxoSmithKline
Completed - verified September 2016

Efficacy and Safety In Poorly Controlled Type 2 Diabetics

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: rosiglitazone
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified September 2016